DL-Buthionine- (S, R) -sulfoximine
DL-Buthionine- (S, R) -sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
Product Specifications
CAS Number
[5072-26-4]
Product Name Alternative
Buthionine sulfoximine; BSO
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Ferroptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/D,L-Buthionine-_S,R_-sulfoximine.html
Purity
99.83
Solubility
H2O : ≥ 50 mg/mL
Smiles
OC(C(N)CCS(CCCC)(=N)=O)=O
Molecular Formula
C8H18N2O3S
Molecular Weight
222.31
Precautions
H302, H315, H319, H335
References & Citations
[1]Griffith OW, et al. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine) . J Biol Chem. 1979 Aug 25;254 (16) :7558-60.|[2]Vanhoefer U, et al. d, l-buthionine- (S, R) -sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996 Dec;2 (12) :1961-8.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
ACS Appl Mater Interfaces. 2025 Apr 2;17 (13) :19367-19381.|Acta Pharmacol Sin. 2025 Jun 23.|Adv Sci (Weinh) . 2023 Aug;10 (22) :e2206798.|Algal Res. 2025 Mar.|Antimicrob Agents Chemother. 2025 Aug 18:e0047125.|Biochem Biophys Res Commun. 2024 Jul 23:733:150436.|Biochem Genet. 2024 Sep 24.|bioRxiv. 2025 March 15.|Cancer Res. 2025 Aug 21.|Cell Death Dis. 2025 Mar 20;16 (1) :193.|Cell Signal. 2025 Jan 3:111583.|Ecotoxicol Environ Saf. 2022 Dec 1:247:114263.|Eur J Med Chem. 2024 Jan 15:264:115997.|FASEB J. 2024 Jul 31;38 (14) :e23844.|Free Radic Biol Med. 2024 Jun 19:S0891-5849 (24) 00531-8.|Gene. 2025 Oct 20:970:149785.|Int Immunopharmacol. 2025 May 11:158:114813.|J Control Release. 2025 Sep 30;388 (Pt 1) :114283.|J Invest Dermatol. 2025 Jul;145 (7) :1693-1705.e2.|Med Oncol. 2023 Apr 10;40 (5) :141.|Mol Carcinog. 2025 Sep 25.|Mol Cell Biochem. 2021 Mar;476 (3) :1631-1642.|Nat Commun. 2024 Aug 30;15 (1) :7522.|Nucleic Acids Res. 2020 Sep 18;48 (16) :9109-9123.|Res Sq. 2024 Sep 12:rs.3.rs-5065904.|Research Square Preprint. 2023 May 24.|Research Square Print. 2023 Mar 24.|Sci Adv. 2025 Aug 22;11 (34) :eadw6926.|Small. 2021 Dec;17 (50) :e2103984.|Redox Biol. 2025 Apr:81:103567.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1398395-01 0.02 mg (E-Coli)
Recombinant Gloeobacter violaceus Heat-inducible transcription repressor HrcA (hrcA)
Sign In for Pricing
View Details 
MBS1398395-02 0.02 mg (Yeast)
Recombinant Gloeobacter violaceus Heat-inducible transcription repressor HrcA (hrcA)
Sign In for Pricing
View Details 
MBS1398395-03 0.1 mg (E-Coli)
Recombinant Gloeobacter violaceus Heat-inducible transcription repressor HrcA (hrcA)
Sign In for Pricing
View Details MBS1398395-04 0.1 mg (Yeast)
Recombinant Gloeobacter violaceus Heat-inducible transcription repressor HrcA (hrcA)
Sign In for Pricing
View Details MBS1398395-05 0.02 mg (Baculovirus)
Recombinant Gloeobacter violaceus Heat-inducible transcription repressor HrcA (hrcA)
Sign In for Pricing
View Details